{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:52:07Z","timestamp":1791665527493,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIH NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtocrr.2026.101066","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:04:18Z","timestamp":1788188658000},"page":"101066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy\u2014A Reanalysis of OAK and POPLAR"],"prefix":"10.1016","volume":"7","author":[{"given":"Jiaqian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nana-Sinkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-1000","authenticated-orcid":false,"given":"Ying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101066_bib1","first-page":"S389","article-title":"Treatment of non-small cell lung cancer (NSCLC)","volume":"5","author":"Zarogoulidis","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtocrr.2026.101066_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2026.101066_bib3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101066_bib4","article-title":"Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics","volume":"15","author":"Abaza","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jtocrr.2026.101066_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (Poplar): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101066_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101066_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2026.101066_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2026.101066_bib9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2026.101066_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-20-3771","article-title":"A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the mystic study","volume":"27","author":"Si","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101066_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101066_bib12","series-title":"BEST (Biomarkers, Endpoints, and Other Tools) Resource. Silver Spring, MD: Food and Drug Administration (US)","year":"2016"},{"key":"10.1016\/j.jtocrr.2026.101066_bib13","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1016\/j.jtho.2016.11.343","article-title":"OA20.01 tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients","volume":"12","author":"Kowanetz","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101066_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.7150\/jca.48105","article-title":"Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)","volume":"12","author":"Ma","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101066_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1780860","article-title":"The predictive efficacy of tumor mutation burden (TMB) on nonsmall cell lung cancer treated by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"2021","author":"Nan","year":"2021","journal-title":"BioMed Res Int"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:46:01Z","timestamp":1791665161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666364326001177"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101066","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy\u2014A Reanalysis of OAK and POPLAR","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101066"}}